Terminal2 · Diagnosis Card #03

Pancreatic Cancer

Evidence-based clinical reference for clinicians, families, and patients navigating pancreatic cancer — celiac plexus pain, exocrine insufficiency, biliary obstruction, malignant ascites, and one of the fastest hospice trajectories in oncology.

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of pancreatic cancer at end of life. What the hospice team needs to understand on day one.

US Cases / Year
~66,000
4th leading cause of cancer death in the US; rising incidence annually.[1]
Stage IV at Presentation
~50%
Most patients have advanced disease at diagnosis — only ~20% are resectable.[2]
5-Year Survival All Stages
~13%
Metastatic disease 5-year survival drops below 3%.[1]
Median Hospice LOS
15–24 days
One of the shortest in all of oncology. Most patients arrive already significantly deconditioned.[1][3]

Pancreatic cancer is one of the most lethal solid tumors in human medicine. The dominant form — pancreatic ductal adenocarcinoma (PDAC) — accounts for approximately 85% of cases and arises from the exocrine ductal cells lining the pancreatic ducts. It is the fourth leading cause of cancer death in the United States and is projected to become the second leading cause by 2030. The five-year survival rate for all stages combined sits near 13%, and for metastatic disease it drops below 3%.[1]

The pancreas is anatomically intimate with structures that make surgical cure rare and symptom control complex: it wraps around the superior mesenteric artery, abuts the portal vein, and sits directly over the celiac plexus — the primary neural highway for upper abdominal pain. Tumors in the pancreatic head (60–70% of cases) cause obstructive jaundice, biliary obstruction, and duodenal obstruction. Tumors in the body/tail grow silently until late, often presenting with cachexia, back pain from celiac plexus invasion, and metastatic disease. Most patients have advanced disease at diagnosis — only about 20% are resectable at presentation.[2]

In the hospice setting, PDAC is uniquely brutal. Severe upper abdominal and back pain from celiac plexus compression, profound and rapid cachexia (85% of patients meet cancer cachexia criteria[15]), malignant biliary obstruction causing pruritus and jaundice, malignant bowel obstruction, ascites from peritoneal disease, and disabling depression — these compound in a patient whose median survival from diagnosis of metastatic disease is roughly 3–6 months. The psychosocial weight is extraordinary, for patient and family alike.[20]

🧭 Clinical framing

Pancreatic cancer arrives at hospice fast and declines faster. Three things define every visit — pain, PERT status, and biliary stent. Start there.

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"Pancreatic cancer compresses time like no other disease I've seen. You walk in thinking you have weeks to build a plan, and the patient is dying before you finish your second visit. The celiac plexus doesn't care about your morphine — it laughs at it. Get ahead of the pain, get the enzymes right, and know that stent status before you sit down. Everything else follows from there."
— Waldo, NP · Terminal2
S02Clinician

How It's Diagnosed

Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.

Diagnostic Workup
  • CT scan (pancreatic protocol): Dual-phase IV contrast — best initial imaging for tumor detection and resectability assessment
  • EUS-FNA: Endoscopic ultrasound with fine-needle aspiration — gold standard for tissue sampling; also used for staging and celiac interventions
  • CA 19-9: Tumor marker; used for monitoring, not diagnosis. Elevated in ~80% of PDAC. Rapidly rising = accelerating disease burden
  • ERCP: Diagnostic and therapeutic for biliary obstruction; stent placement
  • Molecular testing: BRCA1/2, PALB2, ATM germline mutations; KRAS, MSI/dMMR status (pembrolizumab eligibility in MSI-H)
  • Staging: Resectable ~20%, borderline resectable, locally advanced ~30%, metastatic ~50% at presentation
What to Look for in Hospice Records
  • Biliary stent type and date: Plastic stents fail at ~3 months — know what's in place and when it was placed
  • Prior celiac plexus block: If done, note relief duration and whether repeat is feasible
  • CA 19-9 trend: Rapidly rising marker = accelerating disease burden and shortened prognosis
  • Metastatic pattern: Liver-only vs peritoneal vs pulmonary — shapes prognosis conversation
  • BRCA/germline status: Relevant for family genetic counseling even at hospice enrollment — this can save lives in surviving family members

💡 For families

Pancreatic cancer is usually confirmed with a scan and a small tissue sample taken by a specialist. By the time most families are in hospice, these tests are already done — and the focus now is entirely on comfort, not more testing. If you have questions about what the scans showed, your hospice team can explain it in plain language.

S03Everyone

Causes & Risk Factors

Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"

Modifiable Risk Factors
  • Tobacco smoking: 2× increased risk; accounts for ~25% of all PDAC cases
  • Obesity (BMI >30): Independent risk factor, particularly abdominal obesity
  • Type 2 diabetes: Long-standing DM doubles risk; new-onset DM may be a prodrome of PDAC
  • Chronic pancreatitis: ~5% lifetime risk of PDAC; especially alcohol-related
  • Heavy alcohol consumption; high red meat diet; low fruit/vegetable intake
Hereditary & Non-Modifiable
  • BRCA2 mutation: 3–5× increased lifetime risk; ~5–7% of PDAC cases
  • BRCA1 mutation: Moderately elevated risk
  • Lynch syndrome (MLH1, MSH2): 1–4× risk; MSI-H tumors may respond to immunotherapy
  • PALB2, ATM, CDKN2A: Other germline mutations with elevated risk
  • Familial pancreatic cancer: 2 first-degree relatives = 6–9× risk
  • Age over 65; male sex; African American race (higher incidence and mortality)

❤️ For families: "Why did this happen?"

Families almost always ask this. In most cases, there is no single cause — PDAC develops from a combination of aging, genetics, and factors that were often invisible until the cancer was already there. Address guilt directly: "This is not anyone's fault. This disease develops from a combination of aging, genetics, and factors that were invisible until it was already there."

⚕ Clinician note: Genetic counseling

Even at hospice enrollment, offering referral for genetic counseling to family members is appropriate if BRCA2, BRCA1, PALB2, or Lynch syndrome has been identified or suspected. This can save lives in the surviving family.

S04ClinicianEveryone

Treatments & Procedures

What disease-directed treatments this patient may have received. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.

Understanding a patient's treatment history shapes your symptom management strategy, anticipatory guidance, and family conversations. Most hospice patients with PDAC have exhausted 1–3 lines of therapy before enrollment.[17][18]

Surgical Options (Curative Intent)
  • Whipple (pancreaticoduodenectomy): For resectable head tumors; major surgery with significant morbidity; median OS ~20–28 months after resection
  • Distal pancreatectomy + splenectomy: For body/tail tumors
  • Total pancreatectomy: Selected cases; results in surgical diabetes and complete PERT dependence
  • Only ~20% of patients are surgical candidates; neoadjuvant chemo now used to downstage borderline resectable disease
Systemic Therapy (Key Regimens)
  • FOLFIRINOX (5-FU, leucovorin, irinotecan, oxaliplatin): First-line for good PS; OS 11.1 vs 6.8 mo vs gem alone[17]
  • Gem + nab-paclitaxel (MPACT): First-line for moderate PS; OS 8.5 vs 6.7 months
  • Gemcitabine monotherapy: Elderly or PS 2; palliative benefit modest
  • Olaparib (PARP inhibitor): Maintenance in germline BRCA1/2-mutant PDAC after platinum response
  • Pembrolizumab: Only for MSI-H/dMMR PDAC (~1–2% of cases); durable responses possible
Procedural Interventions Relevant to Hospice Clinicians
  • ERCP with biliary stenting (SEMS or plastic): First-line for malignant biliary obstruction; relieves jaundice, pruritus, pain. Metal stents longer patency; plastic stents easier to exchange[10]
  • Percutaneous transhepatic biliary drainage (PTBD): Alternative when ERCP fails; external drain — complex to manage at home
  • EUS-guided celiac plexus neurolysis (EUS-CPN): Ablative injection into celiac plexus; pain relief in 70–90% of patients for 2–3 months[8]
  • Venting PEG (gastrostomy for MBO): Decompression of malignant gastric outlet obstruction; associated with fewer readmissions and higher hospice enrollment
  • Duodenal SEMS: For gastric outlet obstruction; endoscopic placement preferred over surgery in palliative setting
S05Clinician

When Therapy Makes Sense

Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.

There are clinical scenarios where continued or initiated cancer-directed therapy in PDAC remains appropriate, and where palliative care integration alongside treatment (concurrent care model) best serves the patient. Knowing these scenarios prevents premature foreclosure of options.[5][1]

  1. 01
    ECOG 0–1: FOLFIRINOX requires good performance status. Patients tolerating active chemotherapy with measurable disease control should continue.[17]
  2. 02
    BRCA-mutant with olaparib maintenance eligibility: Oral, well-tolerated; improves PFS after platinum response. Do not assume futility in germline BRCA patients.
  3. 03
    MSI-H tumor with pembrolizumab response: Rare (~1–2% of PDAC), but durable responses are possible — do not foreclose this option without confirming MSI status.
  4. 04
    Biliary obstruction managed: A jaundiced patient cannot receive most chemotherapy safely. Stent placement is a prerequisite for systemic therapy in obstructed patients.
  5. 05
    Patient goals explicitly include life-prolongation with full prognosis understanding: A well-informed patient who understands prognosis and chooses active treatment should receive it without judgment.

📊 Key finding

Systematic early palliative care in metastatic PDAC reduced chemotherapy use in the last 30 days of life, increased hospice use, and improved end-of-life quality metrics — without reducing overall survival.[5] Concurrent early palliative care improves QoL without compromising survival.

S06Clinician

When It Doesn't

Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.

The trajectory of pancreatic cancer is notoriously rapid and unforgiving. Ongoing chemotherapy near the end of life in PDAC is consistently associated with increased hospitalizations, ED visits, out-of-pocket costs, and death in hospital — with no survival benefit.[4] Only 39% of metastatic PDAC patients in one study received a palliative care consultation.[1] The system is not referring early enough. You are often the first person to have this conversation.

  1. 01
    ECOG ≥2: Most FOLFIRINOX trials excluded ECOG >1. At ECOG ≥2, the toxicity burden of standard PDAC regimens exceeds benefit in the vast majority of patients.
  2. 02
    Progression through gemcitabine plus FOLFIRINOX: Third-line response rate in PDAC is less than 10%. Continuing cytotoxic therapy at this point causes harm without meaningful benefit.
  3. 03
    Biliary obstruction with stent failure causing cholangitis: Active biliary sepsis from stent occlusion is a medical emergency. Continuing systemic chemotherapy in this setting is not appropriate.
  4. 04
    Severe cachexia: >10% weight loss, albumin <2.5 — the body cannot tolerate additional cytotoxic therapy. Chemotherapy in this context causes suffering, not benefit.
  5. 05
    Estimated survival <3 months: Most PDAC patients at hospice enrollment. Hospice enrollment is appropriate, beneficial, and guideline-supported. Median hospice LOS is 15–24 days.[1][3]

⚠ The oncology handoff

Of 65 NCI-designated cancer centers surveyed, 64 had no policy requiring palliative care involvement in pancreatic cancer patients.[6] Late referral is the norm, not the exception — median hospice enrollment occurs just weeks before death. The hospice NP is often the first clinician to explicitly name the prognosis. Do not assume the oncology team has done this work.

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Celiac Plexus Neurolysis (EUS-CPN)
Grade A
Alcohol neurolysis; EUS or CT-guided; single or bilateral injection
CPN delivers absolute alcohol directly to the celiac plexus neural network, ablating the afferent pain pathway responsible for upper abdominal and back pain in PDAC. Pain relief achieved in 70–92% of patients; opioid requirements decrease significantly at 1–2 months post-procedure.[8][9][11] Duration of relief typically 2–3 months. EUS-CPN is preferred over percutaneous approach due to lower complication risk. Meta-analysis of 10 RCTs confirms efficacy at 4 weeks. Should be considered in any PDAC patient with moderate-severe upper abdominal/back pain inadequately controlled on opioids. Does not require stopping hospice care.
Acupuncture for Pain and Nausea
Grade B
Per certified practitioner; typically 1–2 sessions/week
Multiple RCTs and systematic reviews support acupuncture for cancer-related pain and chemotherapy-induced nausea. In PDAC hospice, useful as adjunct for visceral pain, opioid-induced nausea, and anxiety. Safe when performed by certified practitioner. Avoid needling into ascitic abdomen or areas of skin breakdown.
PERT (Creon) — Pancreatic Enzyme Replacement
Grade A
40,000–80,000 lipase units per meal; 20,000–40,000 per snack; with first bite
Pancreatic enzyme replacement therapy is comfort care, not disease treatment. 85% of PDAC patients have exocrine insufficiency. Creon 40,000–80,000 units per meal with first bite, every meal including snacks. Dramatically improves bloating, steatorrhea, cramping, and nutritional absorption even in final weeks.[14][16] In one study, only 36.9% of PDAC patients received PERT at diagnosis — this is a systematic failure. Prescribe it.
Mirtazapine
Grade B
7.5–15 mg PO QHS
Addresses depression, anorexia, and insomnia with one pill — three of the most common symptoms in PDAC hospice. 7.5–15 mg QHS. Faster onset than SSRIs in this population. Antihistamine properties drive appetite stimulation. One of the most useful drugs in the PDAC comfort toolkit.[19][20]
Paracentesis for Malignant Ascites
Grade A
Therapeutic drainage; repeat every 1–3 weeks PRN
Comfort procedure for malignant ascites from peritoneal carcinomatosis. Relief typically lasts 1–3 weeks. Use frequency as a prognostic clock — taps getting closer together means time is running out. Diuretics work poorly for malignant ascites. Paracentesis is the answer, not spironolactone.
Biliary Stenting (SEMS) for Obstruction
Grade B
ERCP-guided SEMS placement; uncovered or covered metal stents
Malignant biliary obstruction causing jaundice and pruritus is highly distressing and steals quality of life quickly. Endoscopic stenting achieves >90% technical success rate; metal stents have longer patency than plastic stents and are preferred in palliative settings.[13] Clinical benefit — relief of pruritus, improved appetite, reduced fatigue from biliary stasis — is often significant even when prognosis is weeks to months. Know if your patient has a stent: occlusion causes cholangitis, which is a medical emergency.
S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to pancreatic cancer. Patients will use supplements — this section helps you have the right conversation.

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"Patients are going to use supplements whether we ask or not. The conversation is: 'I want to know what you're taking — not to judge you, but because some of these interact with your pain medications and blood thinners.' Say it plainly. Most of the time they're relieved someone asked."
— Waldo, NP
Herb / Supplement Evidence Grade Typical Dose Potential Benefit ⚠ Interactions / Contraindications
Ginger (Zingiber officinale) Grade B 250–1,000 mg/day divided doses Nausea (opioid-induced, MBO-related); antiemetic evidence from CINV trials Mild antiplatelet effect with anticoagulants; mild hypotension; avoid oral form in complete GOO
Curcumin / Turmeric Grade C 500–4,000 mg/day with piperine Preclinical PDAC data; anti-inflammatory for pain and cachexia; safe at standard doses[22][23] CYP3A4 interactions; antiplatelet — bleeding risk in coagulopathic patients; avoid in active biliary obstruction
Melatonin Grade C 3–20 mg PO QHS Some QoL signal in advanced cancer; may improve sleep and reduce fatigue Safe at standard doses; mild additive sedation with opioids/benzos; no significant drug interactions
Mistletoe (Iscador) Grade D Per protocol (varies by formulation) Limited PDAC-specific data; some European palliative use for QoL Discuss with oncology if concurrent treatment; injection site reactions; immunostimulant properties
🚫 Avoid in This Diagnosis
  • High-dose Vitamin E: Antiplatelet — bleeding risk in cachectic patients with coagulopathy
  • St. John's Wort: CYP3A4 — interacts with opioid metabolism and any remaining targeted therapy
  • Ginkgo: Antiplatelet — compounded bleeding risk in thrombocytopenic or coagulopathic patients
  • Cat's Claw: Immunostimulant — avoid with immunosuppressed or infected biliary systems
  • Any supplement that inhibits CYP3A4 in patients on opioids requiring stable blood levels
S09Everyone

Timeline Guide

A guide, not a prediction. PDAC compresses time more aggressively than almost any other cancer. Learn to read the pancreatic cancer clock.

PDAC compresses time more aggressively than almost any other cancer. The median hospice LOS is 15–24 days.[1][3] A patient who appears stable enough for "months" this week can enter active dying in two weeks. Learn to read the pancreatic cancer clock. Every timeline phase below is shaped by biliary status, celiac plexus involvement, and peritoneal disease burden.

YRS–
MOS
Resectable Disease → Active Treatment
  • Surgical candidates (20%): Whipple or distal pancreatectomy ± adjuvant FOLFIRINOX; median OS 20–28 months post-resection
  • Borderline resectable: Neoadjuvant chemo then reassessment; 35–44% surgical conversion rate
  • Locally advanced, no mets: Chemotherapy ± chemoradiation; median OS ~12–18 months with FOLFIRINOX-based regimens
  • Germline BRCA+ with platinum response on olaparib maintenance: PFS extended; durable disease control possible
  • Post-Whipple surveillance: CA 19-9 monitoring, CT every 3–6 months; recurrence rate ~80% within 2 years
MOS–
1 YR
Metastatic Disease — Active Therapy
  • First-line FOLFIRINOX: Median OS 11.1 months vs 6.8 months with gem[17]
  • First-line gem + nab-paclitaxel: Median OS 8.5 months (MPACT trial)
  • Liver mets most common (60–70%); peritoneal spread drives ascites trajectory
  • Rapidly rising CA 19-9 on therapy = progression signal → goals-of-care conversation required now
  • Biliary stent placed — know when it was placed; metal stents last 6–12 months; plastic fail at ~3 months
  • Early pain from celiac plexus involvement: back pain + epigastric pain disproportionate to opioid dose
  • This is when palliative care should be firmly integrated — not at hospice enrollment
WKS–
MOS
Hospice Enrollment Window
  • PS decline to ECOG 3–4; oral intake declining; pain escalating beyond standard opioid management
  • Malignant biliary obstruction requiring stent management; biliary sepsis episodes increasing
  • Celiac plexus pain — opioid-resistant upper abdominal/back pain: trigger CPN conversation now
  • PERT often still missed even at this stage — assess and prescribe at every visit
  • MBO events — venting PEG placed; gastric outlet or duodenal compromise
  • Rapid weight loss; severe cachexia criteria met in 85% of patients
  • Depression peaks; caregiver burden at maximum[20]
  • Average hospice referral in PDAC: shockingly late — median 2–3 weeks before death in many series
DAYS–
WKS
Active Dying Phase — Pre-Active
  • Progressive drowsiness, peripheral shutdown, mottling of knees/ankles first
  • Oral intake ceases; PERT discontinued; comfort meds only via SQ or sublingual
  • Pain can escalate rapidly — continuous SQ infusion (CSCI) of opioid ± midazolam is the answer
  • Ascites requiring frequent paracentesis — taps getting closer together = clock running out
  • Pain crisis possible — have CSCI plan ready before you need it
  • Biliary stent may still be in place — no action needed unless cholangitis symptoms appear (fever + chills + worsening jaundice)
  • Jaundice deepens as hepatic failure progresses — prepare family: this is expected and does not indicate more suffering
  • Comfort kit essential — verify all medications drawn and labeled before this phase
HRS–
DAYS
Final Hours
  • Complete inability to swallow — convert all medications to SQ or sublingual immediately
  • Biliary crisis possible — fever + chills + worsening jaundice in a stented PDAC patient = emergency even in comfort-focused care. Have a plan before you need one.
  • Mottling of knees and feet; mandibular breathing; Cheyne-Stokes pattern
  • Unresponsive or minimally responsive — auditory awareness may persist; speak as if patient can hear
  • Family at bedside — be present, be calm, narrate what is happening
  • Emergency medications: morphine/hydromorphone and midazolam drawn, labeled, and within reach
  • Tell the family: call us first, not 911

⚠ Cholangitis Crisis Protocol

Fever + chills + worsening jaundice in a stented PDAC patient = cholangitis until proven otherwise. This is a medical emergency even in comfort-focused care — have a plan before you need one. Tell the family: call us first, not 911. The ER cannot help this patient the way the hospice team can.

S10Clinician

Medications to Anticipate

Symptom-targeted pharmacology for pancreatic cancer. What to have in the comfort kit, what to titrate first, and what the evidence supports.

Pancreatic cancer hospice requires a broader medication toolkit than most diagnoses. Pain is not managed with a standard comfort kit alone. Biliary symptoms, ascites, PERT, nausea from MBO, and the high rate of delirium near death demand anticipatory prescribing from visit one.[1]

DrugClass / Target SymptomStarting DoseNotes / Cautions
Morphine / Hydromorphone Opioid / Visceral & Celiac Pain Morphine 5–15 mg PO q4h; SQ 2–5 mg q4h First-line; celiac pain often requires higher doses than expected. If not responding to escalation, pursue celiac plexus block — it is not a morphine problem.[8]
PERT (Creon) Exocrine Insufficiency / GI Comfort 40,000–80,000 units/meal; 20,000–40,000/snack With first bite, every meal including snacks. This is comfort care, not disease treatment. Open capsule onto soft food if swallowing difficult.[14][16]
Dexamethasone Corticosteroid / Appetite, Pain Adjunct 4–8 mg PO/SQ daily Appetite, biliary inflammation, periobstructive edema. ⚠ Monitor glucose — PDAC-related diabetes is common.
Mirtazapine Antidepressant / Depression + Anorexia + Insomnia 7.5–15 mg PO QHS Addresses three symptoms with one pill. Faster onset than SSRIs. PDAC has highest rate of depression of any cancer type — screen and treat.[19]
Haloperidol D2 Antagonist / Nausea + Delirium 0.5–2 mg PO/SQ q6–8h Opioid-induced nausea, MBO nausea, delirium at higher doses. Preferred antiemetic via SQ route.
Octreotide Somatostatin / GOO-MBO Nausea 100–300 mcg SQ q8h First-line for MBO at home; reduces GI secretions; can be mixed in CSCI.
Lorazepam Benzodiazepine / Anxiety 0.5–1 mg PO/SQ q4–6h PRN Adjunctive for anxiety; limited evidence for dyspnea alone.
Midazolam Benzodiazepine / Terminal Agitation 2.5–5 mg SQ PRN Terminal agitation, catastrophic symptom management. Have in comfort kit drawn and labeled before this phase.Hepatic metabolism — reduce dose in liver failure.
Glycopyrrolate Anticholinergic / Terminal Secretions 0.2 mg SQ q4h No CNS effects; preferred over hyoscine in conscious patients.
Spironolactone / Furosemide Diuretics / Ascites (Limited Utility) Per protocol ⚠ Work for cardiac/hepatic ascites but work POORLY for malignant ascites. Do not chase the fluid with diuretics. Paracentesis is the answer.

🌿 Symptom Management Decision Tree

Evidence-based · Hospice-adapted
Select a symptom below to begin
What is the primary symptom to address?

🚨 Biliary Crisis Protocol — Know Before You Need It

For patients with biliary stent — know the cholangitis crisis plan before it happens. Fever + rigors + worsening jaundice = call the hospice nurse first, not 911. The ER cannot help this patient the way the hospice team can. Have midazolam and morphine drawn and labeled in the comfort kit. Have the on-call plan clear in the family's hands at every visit.

S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside.

1
Pain that doesn't respond to morphine is a celiac plexus problem
Upper abdominal and back pain in PDAC that doesn't respond to escalating opioids almost always indicates celiac plexus involvement. Stop doubling the morphine and start a celiac plexus neurolysis conversation instead. EUS-CPN provides relief in 70–92% of patients and reduces opioid requirements — this conversation should happen early, not as a last resort.[8][11]
2
PERT is not optional — it is comfort care
Pancreatic exocrine insufficiency (PEI) is present in the vast majority of PDAC patients and causes steatorrhea, bloating, cramping, and severe weight loss. Yet only 36.9% of PDAC patients received PERT at diagnosis in one study.[16] PERT (40,000–80,000 lipase units per meal with first bite of food) dramatically improves GI symptom burden and nutritional absorption even in the final weeks of life. Prescribe it at every visit until the patient stops eating.[14]
3
Know the biliary stent status before every visit
Many PDAC patients have a metal biliary stent (SEMS) in place. Know: when was it placed? Is it a plastic or metal stent? Plastic stents occlude every 3 months — if your patient has a plastic stent and is having rising fevers, RUQ pain, or worsening jaundice, suspect occlusion and cholangitis. This is a medical emergency even in hospice. Metal SEMS last longer (6–12 months) but can still occlude or migrate. The hospice team must have a plan for biliary sepsis before it occurs.
4
Ascites is not a diuretic problem
Malignant ascites from peritoneal carcinomatosis causes early satiety, dyspnea, and profound discomfort. Diuretics are largely ineffective. Do not chase the fluid with spironolactone. Therapeutic paracentesis every 1–2 weeks is legitimate hospice care. Use the frequency as your clock — when taps become more frequent and relief shorter, the prognosis is measured in days.
5
Depression in pancreatic cancer is underdiagnosed and may be biologically driven
PDAC has the highest reported rate of psychiatric comorbidity of any cancer type, and depression frequently precedes the diagnosis by months — suggesting a neuroendocrine or inflammatory mechanism, not purely a psychological response.[20][19] Screen aggressively with PHQ-2 or direct conversation. Mirtazapine (7.5–15 mg qhs) addresses depression, anorexia, and insomnia simultaneously — one of the most useful medications you can prescribe in PDAC hospice. Do not wait for the patient to ask for help with mood.
From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"I've buried more pancreatic cancer patients than I can count, and the one thing I'll never get used to is how fast it happens. You think you have time, and you don't. The morphine isn't working because the problem isn't the morphine — it's the celiac plexus. The patient isn't eating because the enzymes aren't there. The family is terrified because no one told them what jaundice looks like. Fix those three things and you've done more in one visit than most clinicians do in five."
— Waldo, NP · Terminal2
S12EveryoneClinician

Psychosocial & Spiritual Care

Existential distress, depression screening, spiritual assessment, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.

Depression in pancreatic cancer is not just psychological — it may be biologically driven by tumor-secreted cytokines and neuroendocrine disruption. PDAC has the highest rate of psychiatric comorbidity of any cancer type, and depression frequently precedes the diagnosis by months.[19][20] This is not "understandable sadness" — it is a clinical problem requiring treatment. Screen every patient at enrollment.

PDAC compresses the psychosocial trajectory as aggressively as it compresses the clinical one. Families are often in acute shock — diagnosed at stage IV and dead within months. Many never fully process the prognosis before the patient dies. The speed of decline, visible suffering, and complexity of symptoms burn caregivers out faster than almost any other diagnosis.

Psychological Distress Screening
Depression — Screen Every Patient
Grade B

PDAC-specific: depression may be biologically driven — do not attribute it only to "understandable sadness." It is a clinical problem requiring treatment.[19]

  • Single-question screen: "Are you depressed?" has 100% sensitivity in terminally ill populations when phrased directly
  • PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants full PHQ-9
  • Mirtazapine 7.5 mg QHS first-line: Addresses depression, insomnia, and anorexia simultaneously. Faster onset than SSRIs in this population.
  • Distinguish depression from appropriate sadness — both deserve attention; only one warrants pharmacotherapy
Anxiety & Caregiver Distress
Grade B
  • Caregiver anxiety exceeds patient anxiety in PDAC[20] — the speed of decline, visible suffering, and complexity of symptoms burns caregivers out faster than most diagnoses
  • Assess caregiver at every visit as a separate clinical obligation — not as an afterthought
  • Lorazepam 0.5 mg PRN for acute patient anxiety episodes
  • Refer to social work and chaplain at enrollment — not at crisis
  • Dignity therapy: structured life narrative intervention reduces suffering and increases sense of meaning
Spiritual Assessment

Spirituality is not the same as religion. Patients with no religious affiliation still have spiritual needs — meaning, legacy, connection, peace. Use the FICA framework: Faith/beliefs, Importance, Community, Address. Ask: "What gives you strength during this time?"

PDAC patients often have profound peace or profound terror — rarely in between. Ask directly about spiritual distress, legacy, and what they want their family to know. Do not assume you know which one is sitting in front of you.

Clinical Pearl

The "why" question — families almost always ask why this happened. PDAC has no clear behavioral cause in most cases. Address guilt directly: "This is not anyone's fault. This disease develops from a combination of aging, genetics, and factors that were invisible until it was already there." Say these words. They matter.

  1. 01
    Ask about faith community explicitly: "Is there a faith community or spiritual leader who should know you're ill?" Don't assume the answer.
  2. 02
    Involve chaplaincy at enrollment: Spiritual care is a clinical discipline, not an optional add-on. Your job is to open the door — theirs is to walk through it.
  3. 03
    Legacy and meaning work: "What do you most want your family to remember about you?" is both assessment and intervention. It shifts the conversation from dying to living.
  4. 04
    Unfinished business: Relationship ruptures, unresolved guilt, things left unsaid — these are clinical problems with real symptom burden. Don't leave them to chance.
Goals-of-Care Communication
Opening the Conversation
  • "What is your understanding of where things stand with your illness?" — assesses illness understanding before prognostic disclosure
  • "What are you hoping for?" — surfaces values, not just preferences
  • "What are you most afraid of?" — identifies what goals-of-care planning must address
  • "If things got worse, what would matter most to you?" — elicits priorities without triggering defensiveness
  • "Dying at home without pain" is almost universally the goal in PDAC — name it, build the plan around it, and protect it aggressively.
Communication Pitfalls
  • Don't use language of surrender: "Stopping treatment" vs "shifting the focus of care"
  • Don't say "there's nothing more we can do": There is always more to do — it just looks different now
  • Don't conflate hospice with giving up: Frame around what hospice adds, not what it ends
  • Don't have this conversation standing up: Sit down. Make eye contact. Leave silence. The patient will fill it.
  • Involve the family separately when needed: Patients and families often have different goals — both need space to express them
Suicidal Ideation & Hastened Death Requests

Passive wish for death ("I'm ready to go") is common in PDAC and often existentially appropriate — it is not the same as active suicidal ideation. Assessment requires careful distinction: passive wish for death (common, often appropriate), active suicidal ideation with plan (requires immediate psychiatric engagement), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol and conversation). Do not conflate these. Do not avoid the question.

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"I've sat with pancreatic cancer patients who were profoundly at peace and others who were in spiritual agony — and from the outside, you couldn't tell the difference. The ones in agony weren't always crying. Some were very quiet, very polite, very 'I'm fine.' You have to ask. And you have to ask before the disease takes their ability to answer."
— Waldo, NP · Terminal2
S13FamilyEveryone

Family Guide

Plain language for families. Share, print, or read aloud at the bedside.

Caring for someone with pancreatic cancer is one of the hardest things a family can face. This disease moves fast — faster than almost any other cancer. Symptoms can be complex and change quickly. Your loved one's hospice team is here to help manage every one of them, and you are part of that team. What you do in this room matters.

What You May See
  • Deep jaundice (yellowing): The skin, whites of the eyes, and urine may turn yellow or orange. This is expected and does not mean your loved one is in more pain — but it can be alarming. Ask your nurse to explain what it means and what to watch for.
  • Severe weight loss and muscle wasting: Pancreatic cancer causes the body to break down muscle and fat rapidly. This is driven by the disease itself, not by a failure to eat enough.
  • Abdominal distension from ascites: The belly may swell with fluid. The nurse can arrange to have this drained for comfort — it is a routine procedure.
  • Extreme fatigue: Your loved one will sleep more and more. This is the body's natural response to serious illness — not giving up.
  • Nausea especially after eating: There are good medications for this — call the nurse before it becomes a crisis.
  • Confusion in final days: This is a normal part of the dying process as the brain receives less blood flow. Speak calmly and lovingly — hearing is often the last sense to go.
How You Can Help
  • Small frequent meals with enzyme capsules (Creon) with every bite: If your loved one has enzyme pills, give them with every meal and snack — even a cracker. This reduces bloating and stomach discomfort from undigested food.
  • Do not push food: Appetite loss is expected and is caused by the disease, not starvation. Forcing food causes distress, not strength. Small, favorite offerings are enough.
  • Help with drainage if IPC in place: If there is a drain for fluid (peritoneal or biliary), your nurse will show you how to care for it. You can do this.
  • Position for comfort: Semi-recumbent (head elevated 30–45°) reduces abdominal pressure and helps breathing. Use pillows generously.
  • Be present: Silence and touch are profoundly therapeutic. You do not need to fix anything. Being here is the medicine.
📞 Call the nurse immediately if you see:

Fever with chills and worsening yellowing of the skin or eyes (this may be a bile duct infection — a medical emergency) · Sudden severe increase in abdominal pain not helped by current medications · Vomiting that will not stop · Confusion or agitation · Inability to be woken · Any change that frightens you — there is no wrong reason to call.

🙏 Pancreatic cancer moves faster than almost any other disease. You did not miss anything. You are not failing them. Being here — present, calm, loving — is the most important thing you can do. Research shows that patients whose families are present and engaged have better symptom control and less distress.[20] You are part of the care team.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.

  1. 01
    Pancreatic cancer pain that doesn't respond to morphine is not a morphine problem. It's a celiac plexus problem. Stop escalating the opioid and start the conversation about celiac plexus neurolysis. EUS-CPN, CT-guided CPN, or even celiac radiosurgery — all are available, all are compatible with hospice, and all can transform this patient's final weeks. Ask the question early. Don't wait until the patient is in a crisis to wonder if there's something better.
  2. 02
    PERT is not optional. It is comfort care. Eighty-five percent of pancreatic cancer patients have exocrine insufficiency. Bloating, cramping, steatorrhea, greasy diarrhea — these are not inevitable. Creon 40,000–80,000 units per meal with the first bite is not a disease treatment. It is symptom management, dignity preservation, and comfort. If your patient isn't on it, put them on it today. If they are, check the dose and timing.
  3. 03
    Know your patient's biliary stent status before every visit. Plastic stent placed 3 months ago? It's probably failing. Fever + chills + worsening jaundice in a PDAC patient with a stent = cholangitis until proven otherwise. That is a medical emergency even in a comfort-focused patient. Have a plan before you need one. Ask the family to call you first, not 911 — that emergency room visit will not go well.
  4. 04
    Depression in pancreatic cancer is not a mood problem. It may be biology. Screen every patient. Mirtazapine 7.5 mg at bedtime — start here. It addresses depression, anorexia, and insomnia in one pill. It doesn't take 6 weeks to work for mood in actively dying patients the way SSRIs do. And the appetite effect is real. If the patient has 4 weeks left and hasn't slept or eaten in 3, this drug matters more than most of what's in the comfort kit.
  5. 05
    Hospice LOS in pancreatic cancer is 15–24 days. On average. That means your intake visit might be one of five visits total. Act accordingly. Every visit: pain assessment. Every visit: PERT check. Every visit: family education on what to watch for. Every visit: check that the family knows how to use the emergency medications in the comfort kit. There is no time for "we'll address that next week."
  6. 06
    Ascites is not a diuretic problem. Spironolactone and furosemide work beautifully for cardiac and hepatic ascites. They work poorly for malignant ascites from peritoneal carcinomatosis. Don't torture your patient with fluid restriction and diuretics that won't work. Paracentesis every 1–2 weeks for comfort is legitimate hospice care. Use the frequency as your clock — when taps become more frequent and relief shorter, the prognosis is measured in days.
  7. 07
    Jaundice preparation is a clinical skill. Deep icterus — orange-yellow skin, dark brown urine, tea-stained eyes — is visually disturbing for families who have never seen it. Brief them before it happens. Explain what it means, that it is not painful by itself, what to watch for regarding stent failure. Remove the terror. Families who are prepared manage crises better than families who are ambushed by them.
  8. 08
    Opioid disparities are real in pancreatic cancer. Black, Asian, and Hispanic patients receive fewer opioids at lower doses at end of life — documented in Medicare data across GI cancers. When you walk into that home, assess pain without assumptions. Do not let race, age, or ZIP code determine what you prescribe. You are the correction in a system that too often fails these patients.
  9. 09
    Cachectic patients and fentanyl patches are a bad combination. Subcutaneous fat is the depot for transdermal fentanyl. In severe cachexia — which is most PDAC patients — there is no reliable reservoir. Absorption is erratic. The patch looks like it's working and then dumps, or never delivers. Stick to SQ or oral opioids you can titrate. If the patient truly cannot swallow, build a CSCI. Avoid the patch in this population.
  10. 10
    Caregiver anxiety in PDAC is clinically significant. Research shows it exceeds even the patients' own anxiety rates. The speed of this disease, the complexity of symptoms, the visible suffering — families burn out fast and hard. Ask the caregiver directly: "How are you doing?" Not as a formality. As an assessment. Connect them to social work. Make sure they know they can call any time. The caregiver who collapses is the reason for the 3 AM hospital transfer. You are caring for both of them.
— Waldo, NP
REFClinician

References

Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type. 47 peer-reviewed citations.

1
O'Brien J, Halsey B, Connors M, et al. Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer. J Palliat Med. 2025;28(2):217-223.
PMID 39636708 DOIObservational
2
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008-2020.
PMID 32593337 DOIReview
3
Kadakia KC, Trufan SJ, Jagosky MH, et al. Early-onset pancreatic cancer: an institutional series evaluating end-of-life care. Support Care Cancer. 2021;29(7):3613-3622.
PMID 33170401 DOIObservational
4
Bao Y, Maciejewski RC, Garrido MM, et al. Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients With Stage IV Pancreatic Cancer. J Pain Symptom Manage. 2018;55(4):1113-1121.
PMID 29241809 DOIObservational
5
Maltoni M, Scarpi E, Dall'Agata M, et al. Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. Eur J Cancer. 2016;69:110-118.
PMID 27821313 DOIRCT
6
Goyal A, Steinberg A. Survey of NCI-Designated Cancer Centers on the Utilization of Palliative Care in Pancreatic Cancer Patients. Am J Hosp Palliat Care. 2024;42(2):168-171.
PMID 38548621 DOISurvey
7
Lawrence YR, Miszczyk M, Dawson LA, et al. Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(8):1070-1079.
PMID 39029483 DOIPhase 2 Trial
8
Wyse JM, Chen YI, Sahai AV. Celiac plexus neurolysis in the management of unresectable pancreatic cancer: when and how? World J Gastroenterol. 2014;20(9):2186-2192.
PMID 24605017 DOIReview
9
Jones WB, Jordan P, Pudi M. Pain management of pancreatic head adenocarcinomas that are unresectable: celiac plexus neurolysis and splanchnicectomy. J Gastrointest Oncol. 2015;6(4):445-451.
PMID 26261731 DOIReview
10
Michaels AJ, Draganov PV. Endoscopic ultrasonography guided celiac plexus neurolysis and celiac plexus block in the management of pain due to pancreatic cancer and chronic pancreatitis. World J Gastroenterol. 2007;13(26):3575-3580.
PMID 17659707 DOIReview
11
Okita M, Otani K, Gibo N, Matsui S. Systematic review and meta-analysis of celiac plexus neurolysis for abdominal pain associated with unresectable pancreatic cancer. Pain Pract. 2022;22(7):652-661.
PMID 35748531 DOIMeta-Analysis
12
Liu S, Fu W, Liu Z, et al. MRI-guided celiac plexus neurolysis for pancreatic cancer pain: Efficacy and safety. J Magn Reson Imaging. 2016;44(4):923-928.
PMID 27019192 DOIClinical Trial
13
Zhao L, Xu H, Zhang Y. Palliation double stenting for malignant biliary and duodenal obstruction. Exp Ther Med. 2016;11(1):348-352.
PMID 26889267 DOIObservational
14
Whitcomb DC, Buchner AM, Forsmark CE. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Gastroenterology. 2023;165(5):1292-1301.
PMID 37737818 DOIGuideline
15
Hendifar AE, Petzel MQB, Zimmers TA, et al. Pancreas Cancer-Associated Weight Loss. Oncologist. 2019;24(5):691-701.
PMID 30591550 DOIReview
16
Nemer L, Krishna SG, Shah ZK, et al. Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. Pancreas. 2017;46(9):1152-1157.
PMID 28902785 DOIObservational
17
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
PMID 21561347 DOIRCT
18
Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in locally advanced pancreatic cancer (NEOLAP). Lancet Gastroenterol Hepatol. 2021;6(2):128-138.
PMID 33338442 DOIPhase 2 RCT
19
Mayr M, Schmid RM. Depression in pancreatic cancer: sense of impending doom. Digestion. 2010;82(1):1-3.
PMID 20145401 DOIExpert Opinion
20
Janda M, Neale RE, Klein K, et al. Anxiety, depression and quality of life in people with pancreatic cancer and their carers. Pancreatology. 2017;17(2):321-327.
PMID 28153446 DOIObservational
21
Jentzsch V, Davis JAA, Djamgoz MBA. Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management. Cancers (Basel). 2020;12(11):3096.
PMID 33114159 DOIReview
22
Yoshida K, Toden S, Ravindranathan P, Han H, Goel A. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2. Carcinogenesis. 2017;38(10):1036-1046.
PMID 29048549 DOIPreclinical
23
Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 2010;17(3):190-197.
PMID 20214562 DOIReview
24
Karaboga Arslan AK, Uzunhisarcikli E, Yerer MB, Bishayee A. The golden spice curcumin in cancer: A perspective on finalized clinical trials during the last 10 years. J Cancer Res Ther. 2022;18(1):19-26.
PMID 35381757 DOIReview
25
Bigelsen S. Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including curcumin and cannabidiol. Cancer Manag Res. 2018;10:2003-2018.
PMID 30034255 DOIReview
26
Kwon Y, Hu X, Shi KS, et al. Contemporary Patterns of End-of-Life Care Among Medicare Beneficiaries With Advanced Cancer. JAMA Health Forum. 2025;6(2):e245436.
PMID 39982714 DOICohort
27
Duff JM, Thomas RM. Impact of Palliative Chemotherapy and Travel Distance on Hospice Referral in Patients With Stage IV Pancreatic Cancer. Am J Hosp Palliat Care. 2018;35(6):875-881.
PMID 29216749 DOIRetrospective
28
Cullen G. End-of-Life Care: Use of Antineoplastic Therapy and Nonessential Medications in Veteran Patients Receiving Palliative Care. Clin J Oncol Nurs. 2020;24(6):667-672.
PMID 33216053 DOIRetrospective
29
Kondo S, Shimazu T, Morizane C, et al. A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer. BMJ Open. 2014;4(5):e004352.
PMID 24793245 DOIRetrospective
30
Lilley EJ, Scott JW, Goldberg JE, et al. Survival, Healthcare Utilization, and End-of-life Care Among Older Adults With Malignancy-associated Bowel Obstruction: Comparative Study of Surgery, Venting Gastrostomy, or Medical Management. Ann Surg. 2018;267(4):692-699.
PMID 28151799 DOIComparative
31
Goldberg JI, Goldman DA, McCaskey S, Koo DJ, Epstein AS. Illness Understanding, Prognostic Awareness, and End-of-Life Care in Patients With GI Cancer and Malignant Bowel Obstruction With Drainage PEG. JCO Oncol Pract. 2020;17(2):e186-e193.
PMID 32758086 DOIRetrospective
32
Munir MM, Woldesenbet S, Endo Y, et al. Association of Race/Ethnicity, Persistent Poverty, and Opioid Access Among Patients with Gastrointestinal Cancer Near the End of Life. Ann Surg Oncol. 2023;30(13):8548-8558.
PMID 37667099 DOICohort
33
Maire F, Sauvanet A. Palliation of biliary and duodenal obstruction in patients with unresectable pancreatic cancer: endoscopy or surgery? J Visc Surg. 2013;150(3 Suppl):S27-31.
PMID 23597937 DOIReview
34
Kozarek R. Role of preoperative palliation of jaundice in pancreatic cancer. J Hepatobiliary Pancreat Sci. 2013;20(6):567-572.
PMID 23595581 DOIReview
35
Zhu J, Jin Z. Interventional Therapy for Pancreatic Cancer. Gastrointest Tumors. 2016;3(2):81-89.
PMID 27904860 DOIReview
36
Kruse EJ. Palliation in pancreatic cancer. Surg Clin North Am. 2010;90(2):355-364.
PMID 20362791 DOIReview
37
de la Iglesia-García D, Huang W, Szatmary P, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. Gut. 2017;66(8):1354-1355.
PMID 27941156 DOIMeta-Analysis
38
Layer P, Kashirskaya N, Gubergrits N. Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency. World J Gastroenterol. 2019;25(20):2430-2441.
PMID 31171887 DOISys Review
39
Dominguez-Muñoz JE. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2018;34(5):349-354.
PMID 29889111 DOIReview
40
Lounis L, Aurran-Schleinitz T, Turrini O, Delpero JR, Bréjard V. Psychological Outcomes and Quality of Life in Relation to Pancreatectomy: A Systematic Review. Pancreas. 2019;48(4):471-479.
PMID 30973462 DOISys Review
41
Underhill M, Hong F, Lawrence J, Blonquist T, Syngal S. Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer. Psychooncology. 2018;27(7):1711-1718.
PMID 29570238 DOIObservational
42
Ma J, Fang B, Zeng F, et al. Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Toxicol Lett. 2014;231(1):82-91.
PMID 25256401 DOIPreclinical
43
Adsersen M, Chen IM, Rasmussen LS, et al. Regional and age differences in specialised palliative care for patients with pancreatic cancer. BMC Palliat Care. 2021;20(1):192.
PMID 34930211 DOICohort
44
Majeed MH. Home Hospice, Not Hospital. J Pain Palliat Care Pharmacother. 2019;32(4):197-200.
PMID 31050586 DOIExpert Opinion
45
Surges SM, Brunsch H, Jaspers B, et al. Revised European Association for Palliative Care (EAPC) recommended framework on palliative sedation. Palliat Med. 2024;38(5):506-519.
PMID 38297460 DOIConsensus
46
Zhu JW, Jin Z. Interventional endoscopic ultrasound for palliation in pancreatic cancer — celiac plexus and biliary interventions. Gastrointest Tumors. 2016;3(2):81-89.
PMID 27904860 DOIReview
47
Kruse EJ. Palliation in pancreatic cancer: biliary, duodenal, and pain management. Surg Clin North Am. 2010;90(2):355-364.
PMID 20362791 DOIReview

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.